OncoMatch/Clinical Trials/NCT07657325
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma
Is NCT07657325 recruiting? Yes, currently enrolling (Sep 2026). Studying Toripalimab for renal cell carcinoma (rcc).
Treatment: Toripalimab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage PT4, ANY GR. N0, M0, PT ANY STAGE, ANY GR., N+, M0, M1 NED (other)
High risk or M1 NED renal cell carcinoma as defined by the following pathological tumor-node-metastasis and Fuhrman grading status.
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG Performance Status (ECOG PS) of 0 or 1
Prior therapy
Lab requirements
Blood counts
normal bone marrow reserve function; Absolute neutrophil count (ANC)≥1500/µL, Platelets≥100,000/µL, Hemoglobin ≥5.6 mmol/L (9g/dL)
Kidney function
Normal renal function or serum creatinine ≤1.5 mg/dL and/or creatinine clearance ≥30 mL/min for participants with creatinine levels >1.5×institutional ULN
Liver function
Normal liver function or Total bilirubin ≤1.5xULN, or direct bilirubin≤ULN for participants with total bilirubin levels >1.5×ULN; AST (SGOT) and ALT (SGPT) ≤2.5×ULN
Vital organ function meets the following requirements (excluding use of any blood components and cell growth factors within 14 days) : normal bone marrow reserve function; Absolute neutrophil count (ANC)≥1500/µL, Platelets≥100 000/µL, Hemoglobin ≥5.6 mmol/L (9g/dL); Normal renal function or serum creatinine ≤1.5 mg/d and/or creatinine clearance ≥30 mL/min for participants with creatinine levels >1.5×institutional ULN; Normal liver function or Total bilirubin ≤1.5xULN, or direct bilirubin≤ULN for participants with total bilirubin levels >1.5×ULN; AST (SGOT) and ALT (SGPT) ≤2.5×ULN; International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07657325 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage PT4, ANY GR. N0, M0 or PT ANY STAGE, ANY GR., N+, M0 or M1 NED is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages